KRAS innovation moves in a degrader direction at AACR 2025

Despite multiple KRAS inhibitor approvals, innovation against the target has not slowed down, with the focus shifting from mutation-selective small molecules to targeted protein degraders that eliminate the oncogenic protein rather than merely block its active site.

Targeted protein degraders offer advantages over small molecules including higher selectivity and improved pharmacodynamics. In the case of KRAS, pharmacodynamics are the primary driver of degrader innovation. ...